Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 69

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 69
---
 $885.44 billion by 2033, reflecting a compound annual growth rate (CAGR) of 14.80% from 2024 to 2033.

This growth is attributed to increased investment in research and development by pharmaceutical companies, government-led cancer awareness initiatives, and the introduction of advanced therapeutic options.

<div align='center'>42</div>

With such a substantial market size and a strong growth trajectory, novel combination therapies that demonstrate synergy with existing anticancer treatments—particularly those with sales exceeding $60 million—present a significant opportunity.

We believe that our novel nano-candesartan adjuvant approach can play a pivotal role in this space, capturing a meaningful share of the expanding market by improving treatment efficacy and delivering better outcomes for patients.. 5

Liposomal Protein-Loaded Technology – Novel approach in nano particle-based vaccines

There are four (4) different platforms that are used to develop viral vaccines:

| ● | Whole 
 virus |

| ● | Protein-based |

| ● | Viral  
 vector |

| ● | Nucleic 
 acid    |

Virus based vaccines can be live attenuated and inactivated.

The live attenuated vaccine (LAV) requires genetic manipulation to develop low-replication variants of the virus that cannot cause disease but can elicit a similar immune response to that seen in natural infections. It has been linked to genetic instability and the presence of residual virulence. Inactivated vaccines are part of the standard viral vaccination technique. Because these vaccines contain many antigenic components, they have the ability to elicit a wide range of immune responses. In compared to live-attenuated vaccinations, they are said to have less reactogenicity and are associated with lesser immune responses. For inactivated vaccines to be effective, multiple inoculations and powerful adjuvants may be required.

Protein-based vaccines

Subunit vaccines implement purified immunogenic proteins or peptides. For example, the majority of Coronavirus (CoV) subunit vaccines target the Spike protein, particularly its receptor binding domain (RBD) which is highly immunogenic. Vaccination targets include viral structural proteins such as small envelope protein E, envelope spike protein S, nucleocapsid protein N, and matrix protein M. Sever Acute Respiratory Syndrome SARS-CoV RBD antibodies cross-react with the respective protein, and the resultant antisera neutralises the virus, shows that a vaccination targeting the S protein domain could be successful in preventing Coronavirus. The S protein of full-length i.e., S1, S2